One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Cytek Biosciences Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Cytek Biosciences Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Cytek Biosciences Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Cytek Biosciences Inc (CTKB)

Before we jump into Cytek Biosciences Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cytek Biosciences, Inc. cell analysis solutions company. The Company offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The Company has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).

Want to learn more about Cytek Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cytek Biosciences Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Cytek Biosciences Inc’s Stock Price as of Market Close

As of February 14, 2023, 4:00 PM CST, Cytek Biosciences Inc’s stock price was $11.86.

Cytek Biosciences Inc is down 8.77% from its previous closing price of $13.00.

During the last market session, Cytek Biosciences Inc’s stock traded between $12.47 and $13.03. Currently, there are 134.71 million shares of Cytek Biosciences Inc stock available for purchase.

Unfortunately, Cytek Biosciences Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Cytek Biosciences Inc Stock Price History

Cytek Biosciences Inc’s (CTKB) price is currently down 1.58% so far this month.

During the month of February, Cytek Biosciences Inc’s stock price has reached a high of $13.77 and a low of $10.91.

Over the last year, Cytek Biosciences Inc has hit prices as high as $16.05 and as low as $7.38. Year to date, Cytek Biosciences Inc’s stock is down 27.33%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cytek Biosciences Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of February 13, 2023, there were 0 analysts who downgraded Cytek Biosciences Inc’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cytek Biosciences Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Cytek Biosciences Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cytek Biosciences Inc (CTKB) by visiting AAII Stock Evaluator.

Relative Price Strength of Cytek Biosciences Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of February 13, 2023, Cytek Biosciences Inc has a weighted four-quarter relative price strength of -0.64%, which translates to a Momentum Score of 45 and is considered to be Average.

Want to learn more about how Cytek Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cytek Biosciences Inc Stock Price: Bottom Line

As of February 14, 2023, Cytek Biosciences Inc’s stock price is $11.86, which is down 8.77% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Cytek Biosciences Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.